JAMA Cardiol
Enteric-coated vs. uncoated aspirin in patients with CVD
Compared with uncoated aspirin, enteric-coated aspirin wasn't associated with significantly higher risk of MI, stroke, or death, or with lower bleeding risk, regardless of dose, although a reduction in bleeding with enteric-coated aspirin can't be excluded.
- Researchers conducted a post hoc secondary analysis of a study involving 15,076 patients with atherosclerotic CVD with data in the National Patient-Centered Clinical Research Network.
- No significant difference was observed in effectiveness or safety outcomes between enteric-coated aspirin and uncoated aspirin cohorts.
- Additional research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.
Source:
Sleem, A. et al. (2023, October 4). JAMA Cardiol. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/37792369/